ID
25924
Beskrivning
Study ID: 101468/204 Clinical Study ID: 101468/204 Study Title:A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropinirole Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00314860 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome; Restless Legs Syndrome (RLS)
Nyckelord
Versioner (1)
- 2017-09-27 2017-09-27 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
27 september 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
GSK LKA204 Ropinirole in Subjects with Restless Legs Syndrome INTERNATIONAL RLS STUDY GROUP DIAGNOSTIC CRITERIA (RLSDGC)
GSK LKA204 Ropinirole in Subjects with Restless Legs Syndrome INTERNATIONAL RLS STUDY GROUP DIAGNOSTIC CRITERIA (RLSDGC)
Similar models
GSK LKA204 Ropinirole in Subjects with Restless Legs Syndrome INTERNATIONAL RLS STUDY GROUP DIAGNOSTIC CRITERIA (RLSDGC)
C1863322 (UMLS CUI [1,2])
C0030554 (UMLS CUI [1,3])
C1863322 (UMLS CUI [1,2])
C0030554 (UMLS CUI [1,3])
C3890554 (UMLS CUI [1,4])
C1863322 (UMLS CUI [1,2])
C0030554 (UMLS CUI [1,3])
C0026649 (UMLS CUI [1,4])
C1301676 (UMLS CUI [1,5])
C1863322 (UMLS CUI [1,2])
C0030554 (UMLS CUI [1,3])
C0026649 (UMLS CUI [1,4])
C3176727 (UMLS CUI [1,5])